Walleye Capital LLC Sells 129,083 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)

Walleye Capital LLC reduced its holdings in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 13.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 861,301 shares of the biopharmaceutical company's stock after selling 129,083 shares during the period. Walleye Capital LLC owned approximately 1.99% of Abeona Therapeutics worth $5,443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in ABEO. Bank of New York Mellon Corp boosted its stake in shares of Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock worth $515,000 after buying an additional 2,434 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at $151,000. GSA Capital Partners LLP boosted its holdings in Abeona Therapeutics by 54.3% in the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company's stock valued at $607,000 after purchasing an additional 33,831 shares during the period. Citigroup Inc. boosted its holdings in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company's stock valued at $3,897,000 after purchasing an additional 56,332 shares during the period. Finally, Rosalind Advisors Inc. lifted its holdings in Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company's stock worth $11,578,000 after buying an additional 82,000 shares during the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ABEO shares. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, November 25th. Cantor Fitzgerald reiterated an "overweight" rating and set a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. Finally, StockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday.

Abeona Therapeutics Stock Down 0.8 %

NASDAQ:ABEO traded down $0.05 on Monday, reaching $6.34. The stock had a trading volume of 187,399 shares, compared to its average volume of 428,606. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $6.26 and a 200 day moving average of $5.36. The stock has a market cap of $275.60 million, a P/E ratio of -2.38 and a beta of 1.52. Abeona Therapeutics Inc has a 12-month low of $3.05 and a 12-month high of $9.01.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.